Citations

Clear

2511 citation(s) found for "Yang, Ge".

Abstract PO1-19-11: Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for HER2+ Metastatic Breast Cancer (HER2CLIMB-05, Trial in Progress)
Tsurutani, Junji , O’Sullivan, Ciara C. , Tryfonidis, Konstantinos, Santarpia, Libero, Yang, Shan, Hamilton, Erika , Curigliano, Giuseppe , Martín, Miguel , Sohn, Joohyuk , Dièras, Véronique

Mayo Clinic

Cancer Research | May 2, 2024 | Volume: 84 | Issue: 9_Supplement | Pages: PO1-19-11-PO1-19-11

10.1158/1538-7445.sabcs23-po1-19-11 Get It

Abstract Background The current first-line (1L) standard of care (SOC) for human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC) is trastuzumab (T) plus pertuzumab (P) and a taxane. Despite advances in 1L SOC, most patients progress during maintenance therapy with T+P. Tucatinib is a tyrosine kinase inhibitor (TKI) approved in combination with T and capecitabine for adults with HER2+ MBC, with and without brain metastases (BM). In HER2CLIMB, addition of tucatinib significantly prolonged progression-free survival (PFS) and overall survival (OS) in patients with HER2+ MBC and was well tolerated. Adding tucatinib also reduced the risk of disease progression or death in patients with untreated and/or active BM (Murthy et al. NEJM 2020, Curigliano et al. Ann Oncol 2022). HER2CLIMB-05 investigates whether adding tucatinib to 1L SOC as maintenance therapy will extend PFS while maintaining quality of life (QOL). Methods HER2CLIMB-05 (NCT05132582) is a phase 3, randomized, double-blind study evaluating tucatinib plus T+P as maintenance therapy for HER2+ MBC. Approximately 650 patients will be enrolled. Eligible patients will have advanced HER2+ disease, no progression on 4–8 cycles of prior 1L SOC, Eastern Cooperative Oncology Group Performance Status of 0 or 1, and no or asymptomatic BM. Exclusion criteria include prior treatment with anti-HER2 and/or anti-epidermal growth factor receptor TKI (prior SOC for early BC is permitted) or inability to undergo contrast magnetic resonance imaging of the brain. Patients will be randomized 1:1 to receive either tucatinib or placebo twice daily, with T+P once every 21 days. Patients with hormone receptor-positive disease may receive endocrine therapy. The primary endpoint is investigator-assessed PFS. Secondary endpoints include OS, time to deterioration of health-related QOL, central nervous system PFS, safety, and pharmacokinetic (PK) parameters. PFS and OS will be compared using a two-sided stratified log-rank test between treatment groups. Time-to-event endpoints will be summarized using the Kaplan–Meier method. PK and safety data will be summarized using descriptive statistics. Enrollment is ongoing in Austria, Chile, Greece, Italy, Japan, Poland, Portugal, Spain, the US, and several other European, APAC, and LATAM countries. This abstract was previously presented at ESMO-BC 2022, FPN (Final Publication Number): 415, by Veronique Dieras (reused with permission). Citation Format: Erika Hamilton, Junji Tsurutani, Giuseppe Curigliano, Miguel Martín, Ciara O'Sullivan, Joo Hyuk Sohn, Konstantinos Tryfonidis, Libero Santarpia, Shan Yang, Véronique Diéras. Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for HER2+ Metastatic Breast Cancer (HER2CLIMB-05, Trial in Progress) [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO1-19-11.
Crosstalk Between Piezo Channels and the STIM1-Orai1 Pathway Mediates Mechanical Stretch-induced Increases in Intracellular Calcium Signaling in Human Airway Smooth Muscle Cells
Yao, Yang , Borkar, N.A., Zheng, Min , Wang, Sicheng , Zhang, Emily , Vogel, E.R., Prakash, Y.S., Zheng, M., Wang, S., Thompson, Michael A. , Pabelick, Christina M. , Prakash, Y. S.

Mayo Clinic

D30. A NARROW ROAD TO AIRWAY HYPERRESPONSIVENESS | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A7192-A7192

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a7192 Get It

Piezo Channels Modulate Stretch-induced Remodeling and Calcium Regulation in Human Lung Fibroblasts
Zheng, Min , Yao, Yang , Borkar, N.A., Zhang, Emily , Vogel, E.R., Zheng, M., Thompson, Michael A. , Pabelick, Christina M. , Prakash, Y. S.

Mayo Clinic

D30. A NARROW ROAD TO AIRWAY HYPERRESPONSIVENESS | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A7191-A7191

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a7191 Get It

Camlipixant Reduces Burden of Cough-related Urinary Incontinence in Patients With Refractory Chronic Cough in Post-hoc Analysis of A Phase 2b Trial
Taliercio, Rachel M., Birring, Surinder S. , Lanouette, S., Yang, Ronghua , Garin, Margaret , Bonuccelli, Catherine M., Iyer, Vivek , Dicpinigaitis, Peter V. , Smith, John A. , Yang, R.

Mayo Clinic

D25. EMERGING RESEARCH IN COUGH, CYSTIC FIBROSIS AND BRONCHIECTASIS | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A7083-A7083

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a7083 Get It

A randomized phase III double-blind placebo-controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)
Mezzanotte-Sharpe, Jessica , O’Neill, Anne, Arteaga, Carlos L. , Yang, Ximing J. , Cella, David , Meropol, Neal J. , Alpaugh, R. Katherine , Saphner, Thomas J. , Swaney, Robert E., Hoelzer, Karen L., Gradishar, William J. , Sundaram, P. Kothai, Jilani, Shamim Z., Perez, Edith A. , Jahanzeb, Mohammad , Reid, Sonya , Mayer, Ingrid A. , Wagner, Lynne I. , Abramson, Vandana G. , Lin, Nancy U. , Wolff, Antonio C. , Sledge, George W.

Mayo Clinic

No container title available | April 29, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4295044/v1 | PMID 38746356 Get It

Abstract Background In 2008, bevacizumab received accelerated Food and Drug Administration (FDA) approval for use in human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). Based on the preclinical and preliminary clinical activity of the trastuzumab and bevacizumab combination, ECOG-ACRIN E1105 trial was developed to determine if the addition of bevacizumab to a chemotherapy and trastuzumab combination for first-line therapy would improve progression-free survival (PFS) in patients with HER2-positive MBC. Findings: 96 patients were randomized to receive standard first-line chemotherapy and trastuzumab with or without bevacizumab between November 2007 and October 2009, and 93 began protocol therapy. Induction therapy was given for 24 weeks, followed by maintenance trastuzumab with or without bevacizumab. 60% (56/93) began carboplatin and 74% (69/93) completed 6 cycles of induction therapy. Primary endpoint was PFS. Median PFS was 11.1 and 13.8 months for placebo and bevacizumab arms, respectively (hazard ratio [HR] 95%, Confidence Interval [Cl] for bevacizumab vs. placebo: 0.73 [0.43–1.23], p = 0.24), and at a median follow-up of 70.7 months, median survival was 49.1 and 63 months (HR [95% Cl] for OS: 1.09 [0.61–1.97], p = 0.75). The most common toxicities across both arms were neutropenia and hypertension, with left ventricular systolic dysfunction, fatigue, and sensory neuropathy reported more frequently with bevacizumab. Conclusions In this trial, the addition of bevacizumab did not improve outcomes in patients with metastatic HER2-positive breast cancer. Although the trial was underpowered due to smaller than anticipated sample size, these findings corroborated other clinical trials during this time.
Visible Peristalsis in a Patient Referred for Chronic Intestinal Pseudo-Obstruction
Yang, David Yi , Cima, Robert R. , Jencks, Kara J. , Lupianez‐Merly, Camille , Camilleri, Michael , Cima, Robert , Jencks, Kara

Mayo Clinic

American Journal of Gastroenterology | April 26, 2024 | Volume: 120 | Issue: 1 | Pages: 26-26

10.14309/ajg.0000000000002838 | PMID 39745300 Get It

Abstract 13938: Multi-Chamber Strain Characterization Provides Incremental Prognostic Value to Cardiac Damage Staging in Significant Aortic Stenosis
Ye, Zi , Yang, Li‐Tan , Enriquez‐Sarano, Maurice , Michelena, Héctor I.

Mayo Clinic

Circulation | April 23, 2024 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.13938 Get It

Introduction: The survival impact of impaired multi-chamber longitudinal strain in significant tricuspid aortic valve stenosis(TAV-AS) and its relation to cardiac damage staging(CDS) is unknown. Hypothesis: Impaired strain improves prognostication of CDS in significant TAV-AS. Methods: We performed 2D-semi-automated strain analysis in a retrospective cohort of consecutive patients with TAV-AS with mean pressure gradient≥30mmHg on echocardiogram. The outcome was all-cause death. Cutoffs of impaired left-ventricular global longitudinal strain(
Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma
Arnulf, Bertrand , Patel, Krina K. , Cavo, Michèle , Manier, Salomon , Vij, Ravi , Solomon, Scott R. , Delforge, Michel, Truppel-Hartmann, Anna, Yang, Zhihong, Favre‐Kontula, Linda, Piasecki, Julia , Cook, Mark , Rodríguez‐Otero, Paula , Ailawadhi, Sikander , Nooka, Ajay K. , Callander, Natalie S. , Costa, Luciano J. , Bahlis, Nizar Jacques , Moreau, Philippe , Berdeja, Jesús G. , Wu, Fan , Giralt, Sergio

Mayo Clinic

Future Oncology | April 23, 2024 | Volume: 20 | Issue: 18 | Pages: 1221-1235

10.2217/fon-2023-0954 | PMID 38651976 Get It

The Burden of Overweight and Obesity-Associated Gastrointestinal Cancers in Low and Lower-Middle-Income Countries: A Global Burden of Disease 2019 Analysis
Danpanichkul, Pojsakorn , Auttapracha, Thanida , Sukphutanan, Banthoon , Ng, Cheng Han , Wattanachayakul, Phuuwadith , Kongarin, Siwanart , Dutta, Priyata , Duangsonk, Kwanjit , Thongpiya, Jerapas , Seko, Yuya , Noureddin, Mazen , Yang, Ju Dong , Wallace, Michael B. , Muthiah, Mark D , Seko, Yuya , Takahashi, Hirokazu , Yang, Ju Dong , Wijarnpreecha, Karn , Wallace, Michael B , Ng, Cheng Han , Danpanichkul, Pojsakorn , Huang, Daniel Q. , Lui, Rashid , Wijarnpreecha, Karn

Mayo Clinic

American Journal of Gastroenterology | April 22, 2024 | Volume: 119 | Issue: 6 | Pages: 1177-1180

10.14309/ajg.0000000000002819 | PMID 38900306 Get It

INTRODUCTION: Obesity is associated with cancer, including gastrointestinal (GI). Data from low (LICs) and lower-middle-income countries (MICs) are limited. METHODS: We utilized data from the Global Burden of Disease Study 2019 to determine the mortality from GI cancer risk of high body mass index (BMI) in these countries. RESULTS: Mortality rates of GI cancers from high BMI increased in LICs and lower MICs, while burdens decreased or remained stable in high and middle-income countries. DISCUSSION: The GI cancer-related burden from high BMI increased in LICs and lower MICs, necessitating a concerted effort to tackle the obesity pandemic.
Paraneoplastic Calmodulin Kinase‐Like Vesicle‐Associated Protein (CAMKV) Autoimmune Encephalitis
Gilligan, Michael , Lesnick, Connie , Guo, Yong , Nowak, Mihaela, Shah, Maulik , Wittenborn, J. R., Basal, Eati, Hinson, Shannon R., Yang, Binxia , Dubey, Divyanshu , Mills, John R. , Pittock, Sean J. , Ζεκερίδου, Αναστασία , Dubey, Divyanshu , Pittock, S J , Lesnick, Connie E, Bradshaw, Michael , Hinson, Shannon, Dubey, Divyanshu , Zekeridou, Anastasia , McKeon, Andrew , Dubey, Divyanshu , Gilligan, Michael , Ladha, Shafeeq , Wittenborn, John R., Yang, Binxia , McKeon, Andrew

Mayo Clinic

Annals of Neurology | April 18, 2024 | Volume: 96 | Issue: 1 | Pages: 21-33

10.1002/ana.26943 | PMID 38634529 Get It

ObjectivesTo report an autoimmune paraneoplastic encephalitis characterized by immunoglobulin G (IgG) antibody targeting synaptic protein calmodulin kinase‐like vesicle‐associated (CAMKV).MethodsSerum and cerebrospinal fluid (CSF) samples harboring unclassified antibodies on murine brain‐based indirect immunofluorescence assay (IFA) were screened by human protein microarray. In 5 patients with identical cerebral IFA staining, CAMKV was identified as top‐ranking candidate antigen. Western blots, confocal microscopy, immune‐absorption, and mass spectrometry were performed to substantiate CAMKV specificity. Recombinant CAMKV‐specific assays (cell‐based [fixed and live] and Western blot) provided additional confirmation.ResultsOf 5 CAMKV‐IgG positive patients, 3 were women (median symptom‐onset age was 59 years; range, 53–74). Encephalitis‐onset was subacute (4) or acute (1) and manifested with: altered mental status (all), seizures (4), hyperkinetic movements (4), psychiatric features (3), memory loss (2), and insomnia (2). Paraclinical testing revealed CSF lymphocytic pleocytosis (all 4 tested), electrographic seizures (3 of 4 tested), and striking MRI abnormalities in all (mesial temporal lobe T2 hyperintensities [all patients], caudate head T2 hyperintensities [3], and cortical diffusion weighted hyperintensities [2]). None had post‐gadolinium enhancement. Cancers were uterine adenocarcinoma (3 patients: poorly differentiated or neuroendocrine‐differentiated in 2, both demonstrated CAMKV immunoreactivity), bladder urothelial carcinoma (1), and non‐Hodgkin lymphoma (1). Two patients developed encephalitis following immune checkpoint inhibitor cancer therapy (atezolizumab [1], pembrolizumab [1]). All treated patients (4) demonstrated an initial response to immunotherapy (corticosteroids [4], IVIG [2]), though 3 died from cancer.InterpretationCAMKV‐IgG is a biomarker of immunotherapy‐responsive paraneoplastic encephalitis with temporal and extratemporal features and uterine cancer as a prominent oncologic association. ANN NEUROL 2024;96:21–33